Clinical Trials Logo

Buprenorphine clinical trials

View clinical trials related to Buprenorphine.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05505227 Recruiting - Clinical trials for Opioid-Related Disorders

Developing a Tailored Stigma Reduction Intervention to Increase Buprenorphine Prescribing

Start date: September 1, 2022
Phase: N/A
Study type: Interventional

Buprenorphine is an evidence-based treatment for opioid use disorder that also has strong potential to reduce HIV transmission in people who use drugs. Rural health care professionals are eligible and critically needed to provide these medications, but stigma currently limits provider willingness to prescribe buprenorphine, especially in regions where mortality and HIV transmission secondary to opioid use are high. In this developmental trial, the investigators will adapt, refine, and test the feasibility of a prototype brief stigma-reduction training intervention aimed at increasing buprenorphine prescribing in the rural primary care setting.

NCT ID: NCT04480554 Recruiting - Inflammation Clinical Trials

Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1

AMOHI-1
Start date: January 30, 2023
Phase: Phase 2
Study type: Interventional

HIV infection, as well as exposure to opioids (including heroin), are associated with systemic immune activation including increased microbial translocation from the gut. The overall objective of this study is to define the impact of long-term mu-opiate receptor stimulation or blockage with medication for opiate use disorder (i.e, methadone, buprenorphine/naloxone, or extended-release naltrexone) on the kinetics and extent of immune reconstitution on HIV-1 infected people who inject opiate and initiating antiretroviral therapy.